For the last three decades, HER2 has been studied in great detail by clinicians and biologists, as HER2 gene amplification and protein overexpression have been associated with aggressive metastatic breast and ovarian cancers, as well as gastric and bladder cancers [1]. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.